Passage Bio, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PASG research report →
About the company
Passage Bio, Inc. is a biopharmaceutical company dedicated to pioneering genetic therapies for conditions affecting the central nervous system. Their advanced pipeline includes PBGM01, designed to treat infantile GM1 gangliosidosis by utilizing a proprietary AAVhu68 capsid to deliver a functional GLB1 gene, which codes for the lysosomal acid beta-galactosidase enzyme, to both the brain and peripheral tissues.
- CEO
- William Chou
- IPO
- 2020
- Employees
- 60
- HQ
- Philadelphia, PA, US
Price Chart
- Market Cap
- $15.04M
- P/E
- -0.39
- P/S
- 0.00
- P/B
- 1.28
- EV/EBITDA
- 0.37
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -150.88%
- ROIC
- -238.29%
- Revenue
- $0 · 0.00%
- Net Income
- $-45,522,000 · 29.71%
- EPS
- $-14.35 · 33.07%
- Op Income
- $-43,151,000
- FCF YoY
- 34.34%
- 52W High
- $20.00
- 52W Low
- $3.29
- 50D MA
- $5.29
- 200D MA
- $8.32
- Beta
- 1.42
- Avg Volume
- 115.23K
Get TickerSpark's AI analysis on PASG
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 25, 26 | Lynx1 Capital Management LP | buy | 50,055 |
| May 19, 26 | Sondhi Dolan | other | 10,539 |
| May 19, 26 | Porter Derrell | other | 10,539 |
| May 19, 26 | Kassberg Thomas Richard | other | 10,539 |
| May 19, 26 | Kapadia Sandip | other | 10,539 |
| May 19, 26 | GOWEN MAXINE | other | 10,539 |
| May 19, 26 | Countouriotis Athena | other | 10,539 |
| Mar 16, 26 | Borthwick Kathleen | other | 15,610 |
| Mar 16, 26 | Chou William | other | 58,000 |
| Jan 8, 26 | Chou William | other | 10,000 |
Our PASG coverage
Recent articles, reports, and earnings notes.
No research on PASG yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PASG report →Similar companies
Peers in the same neighborhood.